Related Experiment Video

Updated: Aug 8, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

B-cell chronic lymphocytic leukaemia stage 0. An immunophenotypic study of 66 cases and comparison with B small cell

A Stramignoni1, G Valente, M Geuna

  • 1Department of Biomedical Sciences and Human Oncology, University of Torino Medical School, Italy.

European Journal of Haematology
|March 1, 1994
PubMed

Insights

This study defines the immunophenotype of B-cell chronic lymphocytic leukemia (B-CLL) and distinguishes it from other lymphomas. EmR-positive cells (>20%) are key for identifying B-CLL and indicate a better prognosis.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • B-cell chronic lymphocytic leukemia (B-CLL) is a common lymphoid malignancy.
  • Accurate immunophenotyping is crucial for diagnosing B-CLL and differentiating it from other B-cell lymphomas.
  • The immunophenotypic profile of B-CLL requires further refinement for diagnostic and prognostic clarity.

Purpose of the Study:

  • To precisely define the immunophenotype of B-cell chronic lymphocytic leukemia (B-CLL) stage 0.
  • To compare the immunophenotypes of B-CLL with those of diffuse B-cell small cell lymphomas.
  • To identify key markers for distinguishing B-CLL from other lymphocytic lymphomas.

Main Methods:

  • Analysis of 66 B-CLL stage 0 patient cells using a comprehensive panel of monoclonal antibodies.
  • Comparison of B-CLL immunophenotypes with lymph node cells from 51 patients with diffuse B-cell small cell lymphoma.
  • Evaluation of Epstein-Barr virus receptor (EmR) expression as a distinguishing marker.

Main Results:

  • The characteristic immunophenotype of B-CLL stage 0 was identified as SIgM(D)+ EmR+ CD5+ CD9+ CD21+ CD23+ CD35- CD38-.
  • EmR-positive cases predominantly exhibited the leukaemic pattern of B-CLL.
  • EmR-negative cases showed distinct immunophenotypes and histological features, suggesting other lymphoma types.
  • The presence of >20% EmR-positive cells was a significant marker for B-CLL and associated with a better prognosis.
  • Lymphoplasmacytoid/cytic lymphomas presented as either EmR-positive (B-CLL-like) or EmR-negative (distinct profile).

Conclusions:

  • The immunophenotypic analysis successfully differentiated B-CLL from other lymphocytic lymphomas.
  • Epstein-Barr virus receptor (EmR) expression, particularly >20% positivity, is a critical marker for B-CLL diagnosis and prognosis.
  • Distinct subgroups within lymphoplasmacytoid/cytic lymphomas were identified based on EmR expression and immunophenotype, suggesting different biological behaviors.

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

Related Concept Videos